Machine Learning Monitoring for Clinical Deterioration

Not currently recruiting at 2 trial locations
DP
BS
Overseen ByBorna Safabakhsh, MS, MBA
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: AgileMD, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a software tool called eCARTv5, which helps hospital staff identify patients who might deteriorate. It analyzes real-time data, such as vital signs and lab results, to predict if someone might require intensive care or face a risk of dying. The goal is to reduce the duration of ventilator use and hospital stays. It suits adults admitted to specific hospital wards using this monitoring system. As an unphased trial, this study allows patients to contribute to innovative healthcare solutions that could enhance patient outcomes.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on monitoring rather than changing treatments, so you may not need to stop them.

What prior data suggests that this software-based clinical decision support tool is safe for monitoring clinical deterioration?

Research shows that eCARTv5, a software tool, identifies patients who might deteriorate in the hospital. Studies indicate that eCARTv5 predicts patient decline more accurately than older versions and other similar tools. As a result, it can identify more at-risk patients with fewer errors.

Being a software tool, eCARTv5 does not cause physical side effects like medications do. The main concern is its effectiveness and whether it provides accurate alerts to doctors and nurses. The tool has improved over time, suggesting increased reliability. No reports of harm from using the software itself have emerged, so it is considered safe for use in hospitals.12345

Why are researchers excited about this trial?

Researchers are excited about the eCARTv5 clinical deterioration monitoring tool because it leverages machine learning to predict and prevent clinical deterioration in hospitalized patients. Unlike traditional methods that rely on manual monitoring by healthcare staff, eCARTv5 continuously analyzes patient data from electronic health records (EHRs) to provide real-time alerts. This proactive approach has the potential to improve patient outcomes by identifying issues before they become critical, offering a significant advancement over standard observation techniques.

What evidence suggests that the eCARTv5 clinical deterioration monitoring is effective for predicting clinical deterioration?

Research has shown that eCARTv5, a machine learning tool, can effectively predict when hospital patients might deteriorate. One study demonstrated that eCARTv5 alerted medical staff about serious health issues a median of 5 hours before they occurred, much earlier than traditional methods. Another study compared eCARTv5 to six other early warning systems and found it excelled at identifying patients at risk. This trial will include an intervention arm where eCARTv5 will monitor all adult medical-surgical patients at hospitals implementing the tool, and a control arm at hospitals not using eCARTv5. The tool uses real-time data from hospital records to identify potential problems, allowing doctors to act sooner to prevent worse outcomes. Overall, eCARTv5 has strong potential to reduce the need for ventilators, shorten hospital stays, and lower death rates in high-risk patients.23678

Who Is on the Research Team?

DP

Dana P Edelson, MD, MS

Principal Investigator

AgileMD, Inc.

Are You a Good Fit for This Trial?

This trial is for adults over 18 years old who are admitted to specific hospital wards where the eCARTv5 monitoring system is used. It's not open to those under 18 or patients in wards without this technology.

Inclusion Criteria

I am admitted to a unit with eCART monitoring.

Exclusion Criteria

You are not in a hospital unit where patients are monitored using eCART.
I am under 18 years old.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Deployment of eCARTv5 into the EHR workflow to monitor patients and guide clinical teams

12 months

Follow-up

Participants are monitored for outcomes such as mortality, length of stay, and ventilator-free days

12 months

What Are the Treatments Tested in This Trial?

Interventions

  • eCARTv5 clinical deterioration monitoring
Trial Overview The study tests a machine learning tool, eCARTv5, integrated into hospitals' electronic health records. It predicts which patients might soon need intensive care by analyzing their vital signs and lab results.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention ArmExperimental Treatment1 Intervention
Group II: Control ArmActive Control1 Intervention

eCARTv5 clinical deterioration monitoring is already approved in United States for the following indications:

🇺🇸
Approved in United States as eCARTv5 for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

AgileMD, Inc.

Lead Sponsor

Trials
2
Recruited
60,000+

Department of Health and Human Services

Collaborator

Trials
240
Recruited
944,000+

University of Wisconsin, Madison

Collaborator

Trials
1,249
Recruited
3,255,000+

University of Chicago

Collaborator

Trials
1,086
Recruited
844,000+

BayCare Health System

Collaborator

Trials
5
Recruited
30,700+

Biomedical Advanced Research and Development Authority

Collaborator

Trials
108
Recruited
574,000+

Yale University

Collaborator

Trials
1,963
Recruited
3,046,000+

Published Research Related to This Trial

The HAVEN system, developed using data from 230,415 patient admissions, significantly outperforms existing early warning systems in predicting in-hospital deterioration, achieving a c-statistic of 0.901 compared to scores ranging from 0.700 to 0.863.
HAVEN can identify 42% of patients at risk of cardiac arrest or unplanned ICU admissions up to 48 hours in advance, providing a crucial lead time for intervention, which is much higher than the 22% identified by the next best scoring system.
Detecting Deteriorating Patients in the Hospital: Development and Validation of a Novel Scoring System.Pimentel, MAF., Redfern, OC., Malycha, J., et al.[2022]
The study aims to implement a 'Just-in-Time Training' program for nurses using the National Early Warning Score 2 (NEWS2) to enhance early recognition of clinical deterioration in hospitalized patients, which is crucial for improving patient outcomes.
By training nurses to identify early signs of clinical deterioration, the study seeks to reduce mortality rates and the need for emergency interventions, highlighting the importance of timely nursing interventions in patient care.
Nursing Training for Early Clinical Deterioration Risk Assessment: Protocol for an Implementation Study.Lourenço, LBA., Meszaros, MJ., Silva, MFN., et al.[2023]
This systematic review aims to identify and evaluate the automated features, technologies, and algorithms used in electronic early warning/track and triage systems (EW/TTS) designed to predict clinical deterioration, highlighting their potential to improve patient safety.
The study will analyze data from various databases without time limitations, ensuring a comprehensive understanding of current EW/TTS capabilities, which could lead to advancements in fully automated systems for preventing clinical deterioration.
A protocol for a systematic review of electronic early warning/track-and-trigger systems (EW/TTS) to predict clinical deterioration: Focus on automated features, technologies, and algorithms.Rostam Niakan Kalhori, S., Deserno, TM., Haghi, M., et al.[2023]

Citations

A Rapid Diagnostic of Risk in Hospitalized Patients Using ...eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and ...
Early Warning Scores With and Without Artificial IntelligenceIn this cohort study that compared 6 early warning scores across 362 926 patient encounters, eCARTv5, a machine learning model, identified ...
June 21, 2024 AgileMD, Inc. Kelliann Payne Partner Hogan ...The AgileMD eCARTv5 Clinical Deterioration Suite (“eCART”) is a cloud-based software device that is integrated into the electronic health record ...
A Gradient-Boosted Machine-Learning Early Warning ScoreAt the high-risk threshold, eCARTv5 alerted a median of 5 (IQR, 0–43) hours in advance of clinical deterioration, significantly earlier than NEWS (3 hr (IQR, 0– ...
5.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/40138535/
A Gradient-Boosted Machine-Learning Early Warning ScoreeCARTv5 is a gradient-boosted machine model for identifying clinical deterioration, using a gradient-boosted trees algorithm to predict ICU ...
A Gradient-Boosted Machine-Learning Early Warning ScoreWe developed eCARTv5, which performed better than eCARTv2, NEWS, and MEWS retrospectively, prospectively, and across a range of subgroups.
Early Warning Scores With and Without Artificial IntelligenceIn this cohort study of inpatient encounters, eCART outperformed the other AI and non-AI scores, identifying more deteriorating patients with fewer false ...
8.agilemd.comagilemd.com/
AgileMDLearn how AgileMD provides clinical pathways and clinical deterioration early warning software (eCART) that directly integrates into the health system's EHR ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security